ID

34205

Descripción

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01326000

Link

https://clinicaltrials.gov/show/NCT01326000

Palabras clave

  1. 15/1/19 15/1/19 -
  2. 14/5/19 14/5/19 -
Titular de derechos de autor

see on clinicaltrials.gov

Subido en

15 de enero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Colorectal Cancer NCT01326000

Eligibility Colorectal Cancer NCT01326000

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients, >/= 18 years of age
Descripción

ID.1

Tipo de datos

boolean

carcinoma of the colon and/or rectum
Descripción

ID.2

Tipo de datos

boolean

disease progression during or within 6 months of last dose of oxaliplatin containing first-line combination therapy for metastatic disease
Descripción

ID.3

Tipo de datos

boolean

ecog performance status 0-1
Descripción

ID.4

Tipo de datos

boolean

adequate hematological, renal and liver function
Descripción

ID.5

Tipo de datos

boolean

Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with monoclonal antibody/small molecule against epidermal growth factor receptor (egfr)
Descripción

ID.6

Tipo de datos

boolean

prior treatment with irinotecan
Descripción

ID.7

Tipo de datos

boolean

radiotherapy within the last 4 weeks before first dose of study drug (except for limited field palliative radiotherapy for bone pain relief)
Descripción

ID.8

Tipo de datos

boolean

cns metastasis
Descripción

ID.9

Tipo de datos

boolean

history of or active autoimmune disorders/conditions
Descripción

ID.10

Tipo de datos

boolean

Similar models

Eligibility Colorectal Cancer NCT01326000

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
adult patients, >/= 18 years of age
boolean
ID.2
Item
carcinoma of the colon and/or rectum
boolean
ID.3
Item
disease progression during or within 6 months of last dose of oxaliplatin containing first-line combination therapy for metastatic disease
boolean
ID.4
Item
ecog performance status 0-1
boolean
ID.5
Item
adequate hematological, renal and liver function
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
prior treatment with monoclonal antibody/small molecule against epidermal growth factor receptor (egfr)
boolean
ID.7
Item
prior treatment with irinotecan
boolean
ID.8
Item
radiotherapy within the last 4 weeks before first dose of study drug (except for limited field palliative radiotherapy for bone pain relief)
boolean
ID.9
Item
cns metastasis
boolean
ID.10
Item
history of or active autoimmune disorders/conditions
boolean

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial